Peregrine renames Tarvacin to official generic name bavituximab

By Elaine Rigoli

Tampa, Fla., April 24 - Peregrine Pharmaceuticals, Inc. is transitioning from using the trade name Tarvacin for its first-in-class anti-phospholipid agent to bavituximab, the official generic name recently assigned by the U.S. Adopted Names Council.

Bavituximab is in clinical trials for the treatment of hepatitis C viral infections and solid tumors.

The transition is being made partly because of regulatory concerns about potential confusion with marketed or developmental drugs having similar sounding names, according to a news release.

Using the generic name also provides the opportunity for Peregrine to identify separate trade names distinguishing between the oncology and anti-viral clinical programs, a process that has now begun, the release said.

Peregrine is a biopharmaceutical company located in Tustin, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.